Sarepta Therapeutics Business Model Canvas
Rare-disease RNA & gene-therapy Canvas: partnerships, regulatory revenue, high-margin pricing
Sarepta Therapeutics's Business Model Canvas maps its rare-disease focus: differentiated RNA and gene therapies, strategic partnerships, regulatory-driven revenue, and high-margin specialty pricing. This concise snapshot reveals key risks and growth levers. Purchase the full Canvas for a complete, editable strategic playbook.
Partnerships
Academic and Clinical Research Centers
Collaborations with leading neuromuscular and genetic medicine institutes give Sarepta access to patient populations (Duchenne prevalence ~1:3,500–5,000 male births), biomarkers, and translational expertise. Joint studies accelerate target validation and trial enrollment, shortening timelines and lowering attrition. Data sharing and co-authorship amplify scientific credibility and publication impact. These alliances reduce early-stage risk and expand innovation throughput.
Contract Development and Manufacturing Organizations
Specialized CDMOs supply GMP capacity, quality systems and tech-transfer for AAV, oligonucleotide and plasmid manufacturing at clinical and commercial scale, enabling Sarepta to accelerate SRP-9001 and oligo programs. Flexible outsourced capacity lowers Sarepta capex and shortens scale-up timelines, with the cell and gene CDMO market estimated at $6.3B in 2024. Dual-sourcing across geographies mitigates supply risk and supports global rollout.
Patient Advocacy and Foundations
Partnerships with advocacy groups such as Parent Project Muscular Dystrophy, Muscular Dystrophy Association and Muscular Dystrophy UK bolster disease awareness and trial recruitment while providing real-world insights; Duchenne affects about 1 in 3,500–5,000 male births.
Joint programs with these groups have shaped meaningful endpoints and patient support services, and advocacy validation is routinely used in payer and regulator dialogue.
Co-created educational and monitoring resources improve adherence and facilitate outcomes tracking across post‑approval registries.
Regulatory and Health Technology Bodies
Proactive engagement with regulators and HTA bodies enabled Sarepta to pursue accelerated pathways and manage post-marketing commitments, supporting commercial rollout after 2024 approvals and contributing to company revenue near $1.9 billion in 2024.
Early regulatory advice shaped trial design, CMC readiness, and enhanced safety monitoring, reducing time-to-market and informing payer negotiations.
Outcomes frameworks and risk-sharing agreements across multiple European HTAs de-risk launches and harmonize access across geographies.
- Regulatory meetings: targeted early
- Revenue (2024): ~$1.9B
- Outcomes-based agreements: used for multi-country launches
Payers, Specialty Pharmacies, and Distributors
Payers, specialty pharmacies, and distributors underpin Sarepta’s access strategy: value-based contracting and hub distribution maintain patient access and payer alignment for rare-disease therapies; specialty pharmacies coordinate benefits, logistics, and ongoing patient support; ex-US distributors expand market reach; data partnerships enable real-world outcomes measurement to support reimbursement durability.
- Value-based contracts: align payment to outcomes
- Specialty pharmacies: benefits, logistics, adherence
- Ex-US distributors: market expansion
- Data partners: outcomes-driven reimbursement
Partners cut gene therapy risk: CDMO $6.3B, revenue $1.9B
Key partnerships supply patient access, translational expertise, manufacturing scale and payer/advocacy alignment—reducing development risk and speeding commercialization. CDMOs enable GMP AAV/oligo scale (cell & gene CDMO market ~$6.3B in 2024). Advocacy and payer ties support enrollment, endpoints and value-based access; company revenue ~ $1.9B in 2024.
| Partner type | Role | 2024 metric |
|---|---|---|
| Academic/Clinics | Trials, biomarkers | Duchenne ~1:3,500–5,000 |
| CDMOs | GMP scale | $6.3B market |
| Advocacy/Payers | Access, endpoints | Revenue ~$1.9B |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas for Sarepta Therapeutics outlining customer segments (patients, payors, clinicians), channels (specialty clinics, rare-disease networks), and value propositions (novel gene/RNA therapies for Duchenne and rare neuromuscular diseases). It maps key partners, manufacturing and regulatory capabilities, revenue model (high-value therapeutics, partnerships, royalties), plus competitive advantages, risks, and go-to-market strategies for investors and strategists.
Customizable Excel Spreadsheet
High-level view of Sarepta Therapeutics’ business model with editable cells, highlighting how gene therapy innovation, regulatory strategy, and payer access relieve patient and payer pain points in neuromuscular disease treatment.
Activities
Precision Genetic R&D
Design and optimization of RNA-targeted, gene therapy and gene editing programs drive Sarepta’s pipeline expansion, building on three FDA-approved DMD therapies to date. Rigorous preclinical efficacy and safety studies de-risk candidates ahead of INDs and clinical entry. Biomarker development (including dystrophin quantification assays) underpins precise patient selection. Continuous IP filing strategy secures platform advances and freedom to operate.
Clinical Development and Evidence Generation
Phase 1–4 trials validate safety, efficacy and durability across diverse DMD subpopulations, enrolling cohorts from dozens to hundreds per study; DMD affects ~1 in 3,500–5,000 male births. Natural history and registry studies spanning 50+ countries inform endpoints and comparator baselines. Real-world evidence underpins label expansions and payer decisions while long-term follow-up monitors evolving benefit‑risk profiles.
CMC and Manufacturing Scale-Up
Process development at Sarepta focuses on consistent, high-titer vector and oligonucleotide output to meet therapy needs; Duchenne muscular dystrophy prevalence is about 1 in 3,500–5,000 male births (2024), informing demand estimates. Tech transfer and validation enable reliable commercial supply across sites. In-process controls safeguard critical quality attributes. Capacity planning aligns production with global demand scenarios and clinical rollout timelines.
Regulatory, Market Access, and Pharmacovigilance
Regulatory, market access, and pharmacovigilance activities target global filings that leverage expedited pathways and orphan incentives to accelerate patient access for rare neuromuscular therapies.
Health economic models and HTA dossiers quantify value and support price and reimbursement negotiations across major markets.
Robust safety surveillance systems enable continuous risk management, signal detection, and fulfillment of post-marketing commitments and registry obligations.
- Expedited designations and orphan benefits targeted
- HEOR models drive value dossiers for payers
- Safety surveillance for real-time signal detection
- Post-marketing studies and registries ensure compliance
Commercialization and Medical Affairs
Specialty field teams educate prescribers and centers of excellence to support uptake of therapies such as Exondys 51 (approved 2016) and Amondys 45 (approved 2021); medical affairs disseminates peer-reviewed data and engages KOLs to drive evidence adoption. Patient services coordinate access, adherence, and financial support while launch execution aligns activities to targeted geographies and payer landscapes.
- Field coverage: focused on centers of excellence
- Medical affairs: peer-reviewed publications and KOL engagement
- Patient services: access, adherence, financial navigation
- Launch: geography-aligned execution
End-to-end DMD RNA/gene therapy pipeline: trials to launch for 15,000–20,000
Design/optimization of RNA, gene therapy and gene editing programs; rigorous preclinical and Phase 1–4 trials across DMD subtypes; manufacturing scale‑up, tech transfer and QA to meet estimated addressable DMD population ~15,000–20,000 males globally; regulatory/HEOR, safety surveillance, specialty field teams and patient services to enable launch and access.
| Activity | KPI | 2024 |
|---|---|---|
| Trials | Active studies | 20+ |
| Manufacturing | GMP sites | 3–5 |
| Patients | Addressable | 15k–20k |
Delivered as Displayed
Business Model Canvas
The Sarepta Therapeutics Business Model Canvas you’re previewing is the actual deliverable, not a mockup or sample, and reflects the full structure and content you’ll receive after purchase. Upon ordering you’ll get this exact file in editable Word and Excel formats, complete with all sections populated and formatted. No surprises—what you see is the file you’ll download, ready to present, edit, and share.
Rare-disease RNA & gene-therapy Canvas: partnerships, regulatory revenue, high-margin pricing
Sarepta Therapeutics's Business Model Canvas maps its rare-disease focus: differentiated RNA and gene therapies, strategic partnerships, regulatory-driven revenue, and high-margin specialty pricing. This concise snapshot reveals key risks and growth levers. Purchase the full Canvas for a complete, editable strategic playbook.
Partnerships
Academic and Clinical Research Centers
Collaborations with leading neuromuscular and genetic medicine institutes give Sarepta access to patient populations (Duchenne prevalence ~1:3,500–5,000 male births), biomarkers, and translational expertise. Joint studies accelerate target validation and trial enrollment, shortening timelines and lowering attrition. Data sharing and co-authorship amplify scientific credibility and publication impact. These alliances reduce early-stage risk and expand innovation throughput.
Contract Development and Manufacturing Organizations
Specialized CDMOs supply GMP capacity, quality systems and tech-transfer for AAV, oligonucleotide and plasmid manufacturing at clinical and commercial scale, enabling Sarepta to accelerate SRP-9001 and oligo programs. Flexible outsourced capacity lowers Sarepta capex and shortens scale-up timelines, with the cell and gene CDMO market estimated at $6.3B in 2024. Dual-sourcing across geographies mitigates supply risk and supports global rollout.
Patient Advocacy and Foundations
Partnerships with advocacy groups such as Parent Project Muscular Dystrophy, Muscular Dystrophy Association and Muscular Dystrophy UK bolster disease awareness and trial recruitment while providing real-world insights; Duchenne affects about 1 in 3,500–5,000 male births.
Joint programs with these groups have shaped meaningful endpoints and patient support services, and advocacy validation is routinely used in payer and regulator dialogue.
Co-created educational and monitoring resources improve adherence and facilitate outcomes tracking across post‑approval registries.
Regulatory and Health Technology Bodies
Proactive engagement with regulators and HTA bodies enabled Sarepta to pursue accelerated pathways and manage post-marketing commitments, supporting commercial rollout after 2024 approvals and contributing to company revenue near $1.9 billion in 2024.
Early regulatory advice shaped trial design, CMC readiness, and enhanced safety monitoring, reducing time-to-market and informing payer negotiations.
Outcomes frameworks and risk-sharing agreements across multiple European HTAs de-risk launches and harmonize access across geographies.
- Regulatory meetings: targeted early
- Revenue (2024): ~$1.9B
- Outcomes-based agreements: used for multi-country launches
Payers, Specialty Pharmacies, and Distributors
Payers, specialty pharmacies, and distributors underpin Sarepta’s access strategy: value-based contracting and hub distribution maintain patient access and payer alignment for rare-disease therapies; specialty pharmacies coordinate benefits, logistics, and ongoing patient support; ex-US distributors expand market reach; data partnerships enable real-world outcomes measurement to support reimbursement durability.
- Value-based contracts: align payment to outcomes
- Specialty pharmacies: benefits, logistics, adherence
- Ex-US distributors: market expansion
- Data partners: outcomes-driven reimbursement
Partners cut gene therapy risk: CDMO $6.3B, revenue $1.9B
Key partnerships supply patient access, translational expertise, manufacturing scale and payer/advocacy alignment—reducing development risk and speeding commercialization. CDMOs enable GMP AAV/oligo scale (cell & gene CDMO market ~$6.3B in 2024). Advocacy and payer ties support enrollment, endpoints and value-based access; company revenue ~ $1.9B in 2024.
| Partner type | Role | 2024 metric |
|---|---|---|
| Academic/Clinics | Trials, biomarkers | Duchenne ~1:3,500–5,000 |
| CDMOs | GMP scale | $6.3B market |
| Advocacy/Payers | Access, endpoints | Revenue ~$1.9B |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas for Sarepta Therapeutics outlining customer segments (patients, payors, clinicians), channels (specialty clinics, rare-disease networks), and value propositions (novel gene/RNA therapies for Duchenne and rare neuromuscular diseases). It maps key partners, manufacturing and regulatory capabilities, revenue model (high-value therapeutics, partnerships, royalties), plus competitive advantages, risks, and go-to-market strategies for investors and strategists.
Customizable Excel Spreadsheet
High-level view of Sarepta Therapeutics’ business model with editable cells, highlighting how gene therapy innovation, regulatory strategy, and payer access relieve patient and payer pain points in neuromuscular disease treatment.
Activities
Precision Genetic R&D
Design and optimization of RNA-targeted, gene therapy and gene editing programs drive Sarepta’s pipeline expansion, building on three FDA-approved DMD therapies to date. Rigorous preclinical efficacy and safety studies de-risk candidates ahead of INDs and clinical entry. Biomarker development (including dystrophin quantification assays) underpins precise patient selection. Continuous IP filing strategy secures platform advances and freedom to operate.
Clinical Development and Evidence Generation
Phase 1–4 trials validate safety, efficacy and durability across diverse DMD subpopulations, enrolling cohorts from dozens to hundreds per study; DMD affects ~1 in 3,500–5,000 male births. Natural history and registry studies spanning 50+ countries inform endpoints and comparator baselines. Real-world evidence underpins label expansions and payer decisions while long-term follow-up monitors evolving benefit‑risk profiles.
CMC and Manufacturing Scale-Up
Process development at Sarepta focuses on consistent, high-titer vector and oligonucleotide output to meet therapy needs; Duchenne muscular dystrophy prevalence is about 1 in 3,500–5,000 male births (2024), informing demand estimates. Tech transfer and validation enable reliable commercial supply across sites. In-process controls safeguard critical quality attributes. Capacity planning aligns production with global demand scenarios and clinical rollout timelines.
Regulatory, Market Access, and Pharmacovigilance
Regulatory, market access, and pharmacovigilance activities target global filings that leverage expedited pathways and orphan incentives to accelerate patient access for rare neuromuscular therapies.
Health economic models and HTA dossiers quantify value and support price and reimbursement negotiations across major markets.
Robust safety surveillance systems enable continuous risk management, signal detection, and fulfillment of post-marketing commitments and registry obligations.
- Expedited designations and orphan benefits targeted
- HEOR models drive value dossiers for payers
- Safety surveillance for real-time signal detection
- Post-marketing studies and registries ensure compliance
Commercialization and Medical Affairs
Specialty field teams educate prescribers and centers of excellence to support uptake of therapies such as Exondys 51 (approved 2016) and Amondys 45 (approved 2021); medical affairs disseminates peer-reviewed data and engages KOLs to drive evidence adoption. Patient services coordinate access, adherence, and financial support while launch execution aligns activities to targeted geographies and payer landscapes.
- Field coverage: focused on centers of excellence
- Medical affairs: peer-reviewed publications and KOL engagement
- Patient services: access, adherence, financial navigation
- Launch: geography-aligned execution
End-to-end DMD RNA/gene therapy pipeline: trials to launch for 15,000–20,000
Design/optimization of RNA, gene therapy and gene editing programs; rigorous preclinical and Phase 1–4 trials across DMD subtypes; manufacturing scale‑up, tech transfer and QA to meet estimated addressable DMD population ~15,000–20,000 males globally; regulatory/HEOR, safety surveillance, specialty field teams and patient services to enable launch and access.
| Activity | KPI | 2024 |
|---|---|---|
| Trials | Active studies | 20+ |
| Manufacturing | GMP sites | 3–5 |
| Patients | Addressable | 15k–20k |
Delivered as Displayed
Business Model Canvas
The Sarepta Therapeutics Business Model Canvas you’re previewing is the actual deliverable, not a mockup or sample, and reflects the full structure and content you’ll receive after purchase. Upon ordering you’ll get this exact file in editable Word and Excel formats, complete with all sections populated and formatted. No surprises—what you see is the file you’ll download, ready to present, edit, and share.
Description
Rare-disease RNA & gene-therapy Canvas: partnerships, regulatory revenue, high-margin pricing
Sarepta Therapeutics's Business Model Canvas maps its rare-disease focus: differentiated RNA and gene therapies, strategic partnerships, regulatory-driven revenue, and high-margin specialty pricing. This concise snapshot reveals key risks and growth levers. Purchase the full Canvas for a complete, editable strategic playbook.
Partnerships
Academic and Clinical Research Centers
Collaborations with leading neuromuscular and genetic medicine institutes give Sarepta access to patient populations (Duchenne prevalence ~1:3,500–5,000 male births), biomarkers, and translational expertise. Joint studies accelerate target validation and trial enrollment, shortening timelines and lowering attrition. Data sharing and co-authorship amplify scientific credibility and publication impact. These alliances reduce early-stage risk and expand innovation throughput.
Contract Development and Manufacturing Organizations
Specialized CDMOs supply GMP capacity, quality systems and tech-transfer for AAV, oligonucleotide and plasmid manufacturing at clinical and commercial scale, enabling Sarepta to accelerate SRP-9001 and oligo programs. Flexible outsourced capacity lowers Sarepta capex and shortens scale-up timelines, with the cell and gene CDMO market estimated at $6.3B in 2024. Dual-sourcing across geographies mitigates supply risk and supports global rollout.
Patient Advocacy and Foundations
Partnerships with advocacy groups such as Parent Project Muscular Dystrophy, Muscular Dystrophy Association and Muscular Dystrophy UK bolster disease awareness and trial recruitment while providing real-world insights; Duchenne affects about 1 in 3,500–5,000 male births.
Joint programs with these groups have shaped meaningful endpoints and patient support services, and advocacy validation is routinely used in payer and regulator dialogue.
Co-created educational and monitoring resources improve adherence and facilitate outcomes tracking across post‑approval registries.
Regulatory and Health Technology Bodies
Proactive engagement with regulators and HTA bodies enabled Sarepta to pursue accelerated pathways and manage post-marketing commitments, supporting commercial rollout after 2024 approvals and contributing to company revenue near $1.9 billion in 2024.
Early regulatory advice shaped trial design, CMC readiness, and enhanced safety monitoring, reducing time-to-market and informing payer negotiations.
Outcomes frameworks and risk-sharing agreements across multiple European HTAs de-risk launches and harmonize access across geographies.
- Regulatory meetings: targeted early
- Revenue (2024): ~$1.9B
- Outcomes-based agreements: used for multi-country launches
Payers, Specialty Pharmacies, and Distributors
Payers, specialty pharmacies, and distributors underpin Sarepta’s access strategy: value-based contracting and hub distribution maintain patient access and payer alignment for rare-disease therapies; specialty pharmacies coordinate benefits, logistics, and ongoing patient support; ex-US distributors expand market reach; data partnerships enable real-world outcomes measurement to support reimbursement durability.
- Value-based contracts: align payment to outcomes
- Specialty pharmacies: benefits, logistics, adherence
- Ex-US distributors: market expansion
- Data partners: outcomes-driven reimbursement
Partners cut gene therapy risk: CDMO $6.3B, revenue $1.9B
Key partnerships supply patient access, translational expertise, manufacturing scale and payer/advocacy alignment—reducing development risk and speeding commercialization. CDMOs enable GMP AAV/oligo scale (cell & gene CDMO market ~$6.3B in 2024). Advocacy and payer ties support enrollment, endpoints and value-based access; company revenue ~ $1.9B in 2024.
| Partner type | Role | 2024 metric |
|---|---|---|
| Academic/Clinics | Trials, biomarkers | Duchenne ~1:3,500–5,000 |
| CDMOs | GMP scale | $6.3B market |
| Advocacy/Payers | Access, endpoints | Revenue ~$1.9B |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas for Sarepta Therapeutics outlining customer segments (patients, payors, clinicians), channels (specialty clinics, rare-disease networks), and value propositions (novel gene/RNA therapies for Duchenne and rare neuromuscular diseases). It maps key partners, manufacturing and regulatory capabilities, revenue model (high-value therapeutics, partnerships, royalties), plus competitive advantages, risks, and go-to-market strategies for investors and strategists.
Customizable Excel Spreadsheet
High-level view of Sarepta Therapeutics’ business model with editable cells, highlighting how gene therapy innovation, regulatory strategy, and payer access relieve patient and payer pain points in neuromuscular disease treatment.
Activities
Precision Genetic R&D
Design and optimization of RNA-targeted, gene therapy and gene editing programs drive Sarepta’s pipeline expansion, building on three FDA-approved DMD therapies to date. Rigorous preclinical efficacy and safety studies de-risk candidates ahead of INDs and clinical entry. Biomarker development (including dystrophin quantification assays) underpins precise patient selection. Continuous IP filing strategy secures platform advances and freedom to operate.
Clinical Development and Evidence Generation
Phase 1–4 trials validate safety, efficacy and durability across diverse DMD subpopulations, enrolling cohorts from dozens to hundreds per study; DMD affects ~1 in 3,500–5,000 male births. Natural history and registry studies spanning 50+ countries inform endpoints and comparator baselines. Real-world evidence underpins label expansions and payer decisions while long-term follow-up monitors evolving benefit‑risk profiles.
CMC and Manufacturing Scale-Up
Process development at Sarepta focuses on consistent, high-titer vector and oligonucleotide output to meet therapy needs; Duchenne muscular dystrophy prevalence is about 1 in 3,500–5,000 male births (2024), informing demand estimates. Tech transfer and validation enable reliable commercial supply across sites. In-process controls safeguard critical quality attributes. Capacity planning aligns production with global demand scenarios and clinical rollout timelines.
Regulatory, Market Access, and Pharmacovigilance
Regulatory, market access, and pharmacovigilance activities target global filings that leverage expedited pathways and orphan incentives to accelerate patient access for rare neuromuscular therapies.
Health economic models and HTA dossiers quantify value and support price and reimbursement negotiations across major markets.
Robust safety surveillance systems enable continuous risk management, signal detection, and fulfillment of post-marketing commitments and registry obligations.
- Expedited designations and orphan benefits targeted
- HEOR models drive value dossiers for payers
- Safety surveillance for real-time signal detection
- Post-marketing studies and registries ensure compliance
Commercialization and Medical Affairs
Specialty field teams educate prescribers and centers of excellence to support uptake of therapies such as Exondys 51 (approved 2016) and Amondys 45 (approved 2021); medical affairs disseminates peer-reviewed data and engages KOLs to drive evidence adoption. Patient services coordinate access, adherence, and financial support while launch execution aligns activities to targeted geographies and payer landscapes.
- Field coverage: focused on centers of excellence
- Medical affairs: peer-reviewed publications and KOL engagement
- Patient services: access, adherence, financial navigation
- Launch: geography-aligned execution
End-to-end DMD RNA/gene therapy pipeline: trials to launch for 15,000–20,000
Design/optimization of RNA, gene therapy and gene editing programs; rigorous preclinical and Phase 1–4 trials across DMD subtypes; manufacturing scale‑up, tech transfer and QA to meet estimated addressable DMD population ~15,000–20,000 males globally; regulatory/HEOR, safety surveillance, specialty field teams and patient services to enable launch and access.
| Activity | KPI | 2024 |
|---|---|---|
| Trials | Active studies | 20+ |
| Manufacturing | GMP sites | 3–5 |
| Patients | Addressable | 15k–20k |
Delivered as Displayed
Business Model Canvas
The Sarepta Therapeutics Business Model Canvas you’re previewing is the actual deliverable, not a mockup or sample, and reflects the full structure and content you’ll receive after purchase. Upon ordering you’ll get this exact file in editable Word and Excel formats, complete with all sections populated and formatted. No surprises—what you see is the file you’ll download, ready to present, edit, and share.
